Genetic Variations in ABCG2 Gene Predict Breast Carcinoma Susceptibility and Clinical Outcomes after Treatment with Anthracycline-Based Chemotherapy.
Genetic Variations in ABCG2 Gene Predict Breast Carcinoma Susceptibility and Clinical Outcomes after Treatment with Anthracycline-Based Chemotherapy.
复制标题
ABCG2 基因的遗传变异可预测乳腺癌易感性和蒽环类化疗后的临床结果
DOI：
10.1155/2015/279109
复制
发表时间：
2015
影响因子：
--
通讯作者：
Wei M
中科院分区：
文献类型：
--
作者：
Wu H;Liu Y;Kang H;Xiao Q;Yao W;Zhao H;Wang E;Wei M
已知ATP结合盒亚家族G成员2（ABCG 2）的遗传变体参与发展癌症风险和化疗反应的个体间差异。采用PCR-RFLP方法对ABCG 2基因多态性进行基因分型。我们发现ABCG 2 G34 A GA/AA基因型、C421 A AA基因型以及单倍型34 A-421 C和34 G-421 A与乳腺癌发生风险增加显著相关。此外，ABCG 2 C421 AA纯合子在新辅助蒽环类化疗患者中具有显著增强的治疗反应。此外，ABCG 2 G34 A AA基因型携带者在ER阳性或PR阳性患者术后蒽环类药物化疗后显示出更长的OS。这些结果提示ABCG 2基因多态性可能是评估乳腺癌患者易感性和预后的一个候选药物基因组学因素。
The genetic variants of the ATP-binding cassette, subfamily G, member 2 (ABCG2) are known to be involved in developing cancer risk and interindividual differences in chemotherapeutic response. The polymorphisms in ABCG2 gene were genotyped by using PCR-RFLP assays. We found that ABCG2 G34A GA/AA genotype, C421A AA genotype, and haplotypes 34A-421C and 34G-421A were significantly associated with increased risk for developing breast carcinoma. Furthermore, ABCG2 C421A AA homozygote had a significant enhanced therapeutic response in patients with neoadjuvant anthracycline-based chemotherapy. Moreover, ABCG2 G34A AA genotype carriers displayed a longer OS in ER positive patients or PR positive patients after postoperative anthracycline-based chemotherapy. These results suggested that the ABCG2 polymorphisms might be a candidate pharmacogenomic factor to assess susceptibility and prognosis for breast carcinoma patients.